Skip to main content

Advertisement

SpringerLink
Log in

Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the efficacy of intravitreal ranibizumab (IVR) for subfoveal polypoidal choroidal vasculopathy (PCV) in eyes with a best corrected visual acuity (BCVA) of 0.6 (logMAR 0.22) or better.

Methods

Fifty eyes with BCVA between 0.6 (logMAR 0.22) and 1.0 (logMAR 0) and subfoveal PCV were treated with IVR for 3 consecutive months. Additional IVR was given at subsequent monthly visits, if needed, up to 11 months after the initial injection. The patients were followed-up prospectively for 12 months, and changes in mean BCVA, central retinal thickness (CRT), serous retinal detachment (SRD), hemorrhage, and number of polypoidal lesions were evaluated.

Results

Mean BCVA improved significantly at the 3-, 6-, 9-, and 12-month follow-up visits and CRT decreased significantly at 1, 2, 3, 6, 9, and 12 months after the initial treatment as compared with the baseline. SRD was observed in 10 and 21 eyes at 3 and 12 months. Hemorrhage was observed in 6 eyes at 3 months and 3 eyes at 12 months. All polypoidal lesions had completely regressed in 19 % and the size of network vessels was either unchanged or enlarged in 98 % of the eyes at 12 months.

Conclusion

Based on the maintenance of vision improvement for at least 12 months, IVR for PCV proved useful for eyes with BCVAs of 0.6 (logMAR 0.22) to 1.0 (logMAR 0), despite a low regression rate of polypoidal lesions and minimal network size reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.

    Article  PubMed  CAS  Google Scholar 

  2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.

    Article  PubMed  CAS  Google Scholar 

  3. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94:2–13.

    Article  PubMed  CAS  Google Scholar 

  4. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1–8.

    Article  PubMed  CAS  Google Scholar 

  5. Terasaki H, Miyake Y, Suzuki T, Nakamura M, Nagasaka T. Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation. Br J Ophthalmol. 2002;86:321–7.

    Article  PubMed  CAS  Google Scholar 

  6. Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol. 2004;88:809–15.

    Article  PubMed  CAS  Google Scholar 

  7. Nakashizuka H, Mitsumata M, Okisaka S, Shimada H, Kawamura A, Mori R, et al. Clinicopathologic findings in polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2008;49:4729–37.

    Article  PubMed  Google Scholar 

  8. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of subRPE lesions photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453–64.

    Article  PubMed  CAS  Google Scholar 

  9. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J, Leila M, Garcia-Sanchez J. Short-term anatomic effect of ranibizumab for polypoidal choroidal vasculopathy. Eur J Ophthalmol. 2008;18:645–8.

    PubMed  CAS  Google Scholar 

  10. Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, Ariga H, Kosaka S, et al. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Am J Ophthalmol. 2010;150(674–82):e1.

    PubMed  Google Scholar 

  11. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol. 2010;94:297–301.

    Article  PubMed  Google Scholar 

  12. Saito M, Iida T, Kano M. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Retina. 2012;32:1250–9.

    PubMed  CAS  Google Scholar 

  13. Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, et al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol. 2012;154:117–24.

    Article  PubMed  CAS  Google Scholar 

  14. Tano Y. Ophthalmic PDT Study Group. Guidelines for PDT in Japan. Ophthalmology. 2008;115(585):e6.

    PubMed  Google Scholar 

  15. Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina. 2002;22:529–35.

    Article  PubMed  Google Scholar 

  16. Hussain N, Hussain A, Natarajan S. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Indian J Ophthalmol. 2005;53:101–4.

    Article  PubMed  Google Scholar 

  17. Lee SC, Seong YS, Kim SS, Koh HJ, Kwon OW. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula. Ophthalmologica. 2004;218:193–201.

    Article  PubMed  CAS  Google Scholar 

  18. Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111:1576–84.

    Article  PubMed  Google Scholar 

  19. Silva RM, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol. 2005;243:973–9.

    Article  PubMed  CAS  Google Scholar 

  20. Mauget-Faÿsse M, Quaranta-El Maftouhi M, De La Marnièrre E, Leys A. Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy. Eur J Ophthalmol. 2006;16:695–704.

    PubMed  Google Scholar 

  21. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115:141–6.

    Article  PubMed  Google Scholar 

  22. Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2007;51:270–7.

    Article  PubMed  Google Scholar 

  23. Yamashita A, Shiraga F, Shiragami C, Ono A, Tenkumo K. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:465–71.

    Article  PubMed  CAS  Google Scholar 

  24. Uyama M, Wada M, Nagai Y, Matsubara T, Matsunaga H, Fukushima I, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002;133:639–48.

    Article  PubMed  Google Scholar 

  25. Ghajarnia M, Kurup S, Eller A. The therapeutic effects of intravitreal bevacizumab in a patient with recalcitrant idiopathic polypoidal choroidal vasculopathy. Semin Ophthalmol. 2007;22:127–31.

    Article  PubMed  Google Scholar 

  26. Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92:70–3.

    Article  PubMed  CAS  Google Scholar 

  27. Song JH, Byeon SH, Lee SC, Koh HJ, Kwon OW. Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica. 2009;223:85–92.

    Article  PubMed  CAS  Google Scholar 

  28. Sato T, Kishi S, Matsumoto H, Mukai R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149:947–54.

    Article  PubMed  CAS  Google Scholar 

  29. Tsujikawa A, Ooto S, Yamashiro K, Tamura H, Otani A, Yoshimura N. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab. Jpn J Ophthalmol. 2010;54:310–9.

    Article  PubMed  CAS  Google Scholar 

  30. Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina. 2008;28:717–22.

    Article  PubMed  Google Scholar 

  31. Sayanagi K, Gomi F, Sawa M, Ohji M, Tano Y. Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol. 2007;245:1569–71.

    Article  PubMed  Google Scholar 

  32. Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2011;55:39–44.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was funded in part by the Research Committee on Chorioretinal Degenerations and Optic Atrophy, The Ministry of Health and Welfare of Japan (Mitsuko Yuzawa).

Author information

Authors and Affiliations

  1. Department of Ophthalmology, School of Medicine, Surugadai Nihon University Hospital, 1-8-13 Surugadai Kanda, Chiyoda, Tokyo, 101-8309, Japan

    Ryusaburo Mori, Mitsuko Yuzawa, Eriko Akaza & Miho Haruyama

Authors
  1. Ryusaburo Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsuko Yuzawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eriko Akaza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miho Haruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitsuko Yuzawa.

About this article

Cite this article

Mori, R., Yuzawa, M., Akaza, E. et al. Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity. Jpn J Ophthalmol 57, 365–371 (2013). https://doi.org/10.1007/s10384-013-0245-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-013-0245-9

Keywords

Search

Navigation